These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12829647)

  • 1. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
    Chang AM; Jakobsen G; Sturis J; Smith MJ; Bloem CJ; An B; Galecki A; Halter JB
    Diabetes; 2003 Jul; 52(7):1786-91. PubMed ID: 12829647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL; Holst JJ; Vølund A; Madsbad S
    Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
    Agersø H; Jensen LB; Elbrønd B; Rolan P; Zdravkovic M
    Diabetologia; 2002 Feb; 45(2):195-202. PubMed ID: 11935150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.
    Ribel U; Larsen MO; Rolin B; Carr RD; Wilken M; Sturis J; Westergaard L; Deacon CF; Knudsen LB
    Eur J Pharmacol; 2002 Sep; 451(2):217-25. PubMed ID: 12231394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
    Madsbad S; Schmitz O; Ranstam J; Jakobsen G; Matthews DR;
    Diabetes Care; 2004 Jun; 27(6):1335-42. PubMed ID: 15161785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
    Harder H; Nielsen L; Tu DT; Astrup A
    Diabetes Care; 2004 Aug; 27(8):1915-21. PubMed ID: 15277417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    Larsen J; Hylleberg B; Ng K; Damsbo P
    Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
    Elbrønd B; Jakobsen G; Larsen S; Agersø H; Jensen LB; Rolan P; Sturis J; Hatorp V; Zdravkovic M
    Diabetes Care; 2002 Aug; 25(8):1398-404. PubMed ID: 12145241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
    Agersø H; Vicini P
    Eur J Pharm Sci; 2003 Jun; 19(2-3):141-50. PubMed ID: 12791417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
    Feinglos MN; Saad MF; Pi-Sunyer FX; An B; Santiago O;
    Diabet Med; 2005 Aug; 22(8):1016-23. PubMed ID: 16026367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
    Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
    Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
    Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
    Rolin B; Larsen MO; Gotfredsen CF; Deacon CF; Carr RD; Wilken M; Knudsen LB
    Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E745-52. PubMed ID: 12217892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
    Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
    Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.